Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Interview

An educated approach: AI-enabled neoantigen vaccine R&D

Roman Yelensky


INNOVATION INSIGHTS


ROMAN YELENSKY is Gritstone Oncology’s first employee and serves as chief technology officer, with responsibility for the EDGE tumor antigen identification platform. Previously, Dr Yelensky was vice president at Foundation Medicine, which he joined at its inception. At Foundation Medicine, he co-led sequence data analysis for FoundationOne and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Dr Yelensky established Foundation Medicine’s FDA-regulated products program, leading to FDA approval of the first NGS-based companion diagnostic. He holds a PhD in bioinformatics and genomics from the Massachusetts Institute of Technology and has co-authored more than 75 manuscripts, including most recently on EDGE in Nature Biotechnology.

DOI: 10.18609/cgti.2020.069
Citation: Cell & Gene Therapy Insights 2020; 6(4), 591–595
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog